15.1 C
Delhi
Friday, January 16, 2026

Tag: US FDA approvals

Sun Pharma Q2FY26 Net Profit Rises 2.5% to Rs 3,118 Crore

Sun Pharma reports 9% revenue growth in Q2FY26 with innovative US medicines surpassing generics for the first time. Strong EBITDA margin at 31.3%.